Patent US4731375A successfully refreshed from Google Patents.
US4731375A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Coumarin derivatives and antiallergic agents containing the same
Assignee: Kaken Pharmaceutical Co Ltd
•
Filing: 1985-12-09
•
Granted: 1988-03-15
•
Expires: 2005-12-09
Abstract
Abstract A chromene derivative having the general formula (I): <IMAGE> (I) wherein n is 1 to 5 and -O-CH2)nCO2H group is attached to 5-position, 6-position, 7-position or 8-position, or salts thereof, a process for preparing the same and antiallergic agents containing the same. The compounds of the present invention inhibit the immunological release of chemical mediators such as SRS-A and histamine from mast cell and have an excellent effect in preventing and treating the various allergic diseases such as allergic asthma, allergic dermatitis, allergic nasitis, hives, allergic enteritis and allergic conjunctivitis, especially allergic asthma.
Inventors
- 👤 Jun Nakano
- 👤 Toshikazu Awaji
- 👤 Kiyoshi Kuriyama
- 👤 Yoshiyuki Hiyama
- 👤 Toshiaki Okuda
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:25
CPC Classifications
C; C07; C07D; C07D405/00; C07D405/02; C07D405/04; A; A61; A61P; A61P37/00; A61P37/08
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
42 words
A chromene derivative having the general formula (I): ##STR7## wherein n is 1 to 5 and the --O--CH 2 ) n CO 2 H group is attached at 5-position, 6-position, 7-position or 8-position of the chromene ring, and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
42 words
A chromene derivative having the general formula (I): ##STR7## wherein n is 1 to 5 and the --O--CH 2 ) n CO 2 H group is attached at 5-position, 6-position, 7-position or 8-position of the chromene ring, and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is [2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-8-yloxy]acetic acid.
Claim 4
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is 4-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-8-yloxy]butyric acid.
Claim 5
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is 4-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-6-yloxy]butyric acid.
Claim 6
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-8-yloxy]hexanoic acid.
Claim 7
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-7-yloxy]hexanoic acid.
Claim 8
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-6-yloxy]hexanoic acid.
Claim 9
Dependent Claim
20 words
The chromene derivative and pharmaceutically acceptable salts thereof as defined in claim 1, wherein the chromene derivative is 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-5-yloxy]hexanoic acid.
Claim 10
Dependent Claim
65 words
A pharmaceutical composition which comprises: an antiallergic effective amount of a chromene derivative selected from the group consisting of compounds according to formula (I) ##STR8## wherein n is 1 to 5 and the --O--(CH 2 ) n --CO 2 H group is attached at the 5-position, 6-position, 7-position or 8-position of the chromene ring and the pharmaceutically acceptable salts thereof; and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
65 words
A pharmaceutical composition which comprises: an antiallergic effective amount of a chromene derivative selected from the group consisting of compounds according to formula (I) ##STR8## wherein n is 1 to 5 and the --O--(CH 2 ) n --CO 2 H group is attached at the 5-position, 6-position, 7-position or 8-position of the chromene ring and the pharmaceutically acceptable salts thereof; and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein said chromene derivative is selected from the group consisting of 3-oxo-3-(1H-tetrazole-5-yl)-[2H-chromene-8-yloxy]acetic acid and pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein the chromene derivative is selected from the group consisting of 4-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-8-yloxy]butyric acid and pharmaceutically acceptable salts thereof.
Claim 14
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein the chromene derivative is selected from the group consisting of 4-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-6-yloxy]butyric acid and pharmaceutically acceptable salts thereof.
Claim 15
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein the chromene derivative is selected from the group consisting of 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-8-yloxy]hexanoic acid and pharmaceutically acceptable salts thereof.
Claim 16
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein the chromene derivative is selected from the group consisting of 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-7-yloxy]hexanoic acid and pharmaceutically acceptable salts thereof.
Claim 17
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein the chromene derivative is selected from the group consisting of 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-6-yloxy]hexanoic acid and pharmaceutically acceptable salts thereof.
Claim 18
Dependent Claim
25 words
A pharmaceutical composition according to claim 9, wherein the chromene derivative is selected from the group consisting of 6-[2-oxo-3-(1H-tetrazole-5-yl)-2H-chromene-5-yloxy]hexanoic acid and pharmaceutically acceptable salts thereof.
References Cited (Backward Citations)
US3600437A
Cited
US4406908A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-03-15 | 1991-09-14 | 1992-03-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-03-15 | 1995-09-14 | 1996-03-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-03-15 | 1999-09-14 | 2000-03-15 | $7700.00 | Window Closed / Lapsed |